FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an antibody for a member of the tumor necrosis factor receptor superfamily 25 (TNFRSF25) or its antigen-binding fragment, as well as to a composition and product containing it. Also disclosed is the use of the above antibody or its fragment to stimulate proliferation of CD8+ T cells in a cancer patient, to obtain an immune response in a cancer patient, and to stimulate the proliferation of regulatory CD4+FoxP3+ T cells in a cancer patient.
EFFECT: invention makes it possible to effectively treat cancer involving TNFRSF25-expressing tumor cells.
18 cl, 7 tbl, 3 ex, 13 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
